Wall Street brokerages forecast that Dexcom (NASDAQ:DXCM) will report sales of $204.46 million for the current fiscal quarter, Zacks reports. Eleven analysts have issued estimates for Dexcom’s earnings, with estimates ranging from $197.00 million to $210.90 million. Dexcom posted sales of $170.60 million in the same quarter last year, which would indicate a positive year over year growth rate of 19.8%. The firm is expected to issue its next quarterly earnings report on Tuesday, August 7th.
According to Zacks, analysts expect that Dexcom will report full-year sales of $860.68 million for the current year, with estimates ranging from $854.90 million to $875.48 million. For the next fiscal year, analysts forecast that the business will report sales of $999.37 million per share, with estimates ranging from $971.01 million to $1.04 billion. Zacks’ sales averages are an average based on a survey of research firms that cover Dexcom.
Dexcom (NASDAQ:DXCM) last issued its quarterly earnings data on Wednesday, May 2nd. The medical device company reported ($0.32) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.32). Dexcom had a negative return on equity of 9.32% and a negative net margin of 4.30%. The business had revenue of $184.40 million during the quarter, compared to analyst estimates of $172.66 million. During the same period in the previous year, the firm earned ($0.49) EPS. Dexcom’s quarterly revenue was up 29.6% compared to the same quarter last year.
Dexcom opened at $99.72 on Monday, Marketbeat.com reports. Dexcom has a twelve month low of $42.62 and a twelve month high of $102.10. The company has a debt-to-equity ratio of 0.79, a current ratio of 5.83 and a quick ratio of 5.42. The company has a market cap of $8.78 billion, a price-to-earnings ratio of -171.93 and a beta of -0.01.
In related news, EVP Richard Doubleday sold 2,581 shares of the stock in a transaction on Friday, March 23rd. The stock was sold at an average price of $68.44, for a total value of $176,643.64. Following the sale, the executive vice president now owns 94,429 shares in the company, valued at approximately $6,462,720.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jay S. Skyler sold 31,464 shares of the stock in a transaction on Tuesday, May 8th. The shares were sold at an average price of $85.11, for a total value of $2,677,901.04. Following the completion of the sale, the director now owns 4,553 shares in the company, valued at approximately $387,505.83. The disclosure for this sale can be found here. In the last three months, insiders sold 128,375 shares of company stock valued at $11,114,875. 1.80% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. raised its stake in Dexcom by 2.3% in the 1st quarter. BlackRock Inc. now owns 3,887,488 shares of the medical device company’s stock valued at $288,296,000 after acquiring an additional 87,973 shares during the period. JPMorgan Chase & Co. raised its stake in Dexcom by 8.9% in the 1st quarter. JPMorgan Chase & Co. now owns 2,588,232 shares of the medical device company’s stock valued at $191,943,000 after acquiring an additional 211,250 shares during the period. AXA raised its stake in Dexcom by 44.9% in the 4th quarter. AXA now owns 1,911,206 shares of the medical device company’s stock valued at $109,684,000 after acquiring an additional 592,275 shares during the period. William Blair Investment Management LLC raised its stake in Dexcom by 24.3% in the 4th quarter. William Blair Investment Management LLC now owns 1,762,619 shares of the medical device company’s stock valued at $101,157,000 after acquiring an additional 344,294 shares during the period. Finally, OppenheimerFunds Inc. increased its position in Dexcom by 96.5% during the 4th quarter. OppenheimerFunds Inc. now owns 1,495,535 shares of the medical device company’s stock worth $85,829,000 after buying an additional 734,325 shares during the period.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.